US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5780446A
(en)
*
|
1996-07-09 |
1998-07-14 |
Baylor College Of Medicine |
Formulations of vesicant drugs and methods of use thereof
|
US6368598B1
(en)
|
1996-09-16 |
2002-04-09 |
Jcrt Radiation Oncology Support Services, Inc. |
Drug complex for treatment of metastatic prostate cancer
|
US6552060B1
(en)
|
1997-08-11 |
2003-04-22 |
Prolx Pharmaceuticals, Inc. |
Asymmetric disulfides and methods of using same
|
US20030176512A1
(en)
*
|
1998-08-11 |
2003-09-18 |
Kirkpatrick D. Lynn |
Asymmetric disulfides and methods of using same
|
US6262271B1
(en)
*
|
1997-10-14 |
2001-07-17 |
The Scripps Research Institute |
ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins
|
WO1999029642A1
(fr)
*
|
1997-12-08 |
1999-06-17 |
The Scripps Research Institute |
Synthese d'analogues de cc-1065/duocarmycine
|
US20030003507A1
(en)
*
|
1999-06-02 |
2003-01-02 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2370003C
(fr)
|
1999-01-13 |
2008-08-19 |
Tracey Brown |
Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
|
IL138990A0
(en)
|
1999-02-12 |
2001-11-25 |
Biostream Inc |
Matrices for drug delivery and methods for making and using the same
|
WO2001024763A2
(fr)
|
1999-10-01 |
2001-04-12 |
Immunogen, Inc. |
Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
|
JP2003514903A
(ja)
|
1999-11-24 |
2003-04-22 |
イムノージェン インコーポレーテッド |
タキサンを含有する細胞傷害薬とその治療への利用
|
DE60026065T2
(de)
*
|
1999-12-03 |
2006-10-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Elektropolymerisierbare monomere und polymerbeschichtungen auf implantierbaren geräten
|
US20060013850A1
(en)
*
|
1999-12-03 |
2006-01-19 |
Domb Abraham J |
Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
AU2001269885A1
(en)
*
|
2000-06-14 |
2001-12-24 |
The Scripps Research Institute |
Distamycin a analogs
|
AUPQ879500A0
(en)
*
|
2000-07-14 |
2000-08-10 |
Meditech Research Limited |
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
US9066919B2
(en)
|
2000-07-14 |
2015-06-30 |
Alchemia Oncology Pty Limited |
Hyaluronan as a chemo-sensitizer in the treatment of cancer
|
JP2004529887A
(ja)
*
|
2001-02-22 |
2004-09-30 |
スクール オブ ファーマシー, ユニヴァーシティ オブ ロンドン |
腫瘍治療のためのプロドラッグとしてのピロロ−インドールおよびピロロ−キノリン誘導体
|
US7157458B2
(en)
*
|
2001-04-17 |
2007-01-02 |
Cryolife, Inc. |
Bifunctional energy-reversible acyl-compositions
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
DK2163256T3
(en)
|
2001-05-11 |
2015-12-07 |
Ludwig Inst For Cancer Res Ltd |
Specific binding proteins and use thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
CN101671335A
(zh)
|
2001-05-31 |
2010-03-17 |
梅达莱克斯公司 |
细胞毒素、其有用的前体药物、连接基团和稳定剂
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
JP4619651B2
(ja)
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
WO2003018062A1
(fr)
*
|
2001-08-27 |
2003-03-06 |
Meditech Research Limited |
Protocoles therapeutiques ameliores
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
DE10147672A1
(de)
|
2001-09-27 |
2003-04-10 |
Bayer Ag |
Substituierte 2,5-Diamidoindole und ihre Verwendung
|
AU2002366803A1
(en)
|
2001-12-19 |
2003-07-09 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
|
US6756397B2
(en)
*
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
WO2003090600A2
(fr)
*
|
2002-04-23 |
2003-11-06 |
Genentech, Inc. |
Compositions et procedes permettant de diagnostiquer et de traiter une tumeur
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US7202346B2
(en)
*
|
2002-07-03 |
2007-04-10 |
Immunogen Inc. |
Antibodies to non-shed Muc1 and Muc16, and uses thereof
|
CA2494074A1
(fr)
|
2002-08-02 |
2004-02-12 |
Immunogen, Inc. |
Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
JP2006505571A
(ja)
*
|
2002-10-15 |
2006-02-16 |
リゲル ファーマシューテイカルズ、インコーポレイテッド |
置換されたインドール及びhcv阻害剤としてのその使用
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
MX369959B
(es)
*
|
2003-05-14 |
2019-11-27 |
Immunogen Inc |
Composicion de farmaco conjugado.
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
EP1713900A4
(fr)
*
|
2004-01-27 |
2009-06-17 |
Compugen Ltd |
Procedes et systemes pour l'annotation de sequences de biomolecules
|
WO2005071059A2
(fr)
*
|
2004-01-27 |
2005-08-04 |
Compugen Ltd. |
Procede d'identification de produits genetiques putatifs par comparaison de sequences inter-especes et de sequences de biologie moleculaire exposees par celles-ci
|
EP1740601B1
(fr)
|
2004-04-21 |
2012-12-05 |
The University of Chicago |
Inhibiteurs de kinase a chaine legere de myosine et procede d'utilisation
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
NZ550934A
(en)
*
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
BRPI0512928A
(pt)
*
|
2004-06-30 |
2008-04-15 |
Novartis Ag |
composições e métodos para liberação de agentes de antitumor
|
CA2486285C
(fr)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugues ciblant des cellules a expression du syndecan-1 et utilisation de ceux-ci
|
WO2006086733A2
(fr)
|
2005-02-11 |
2006-08-17 |
Immunogen, Inc. |
Procede pour preparer des conjugues medicamenteux stables
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
EP2384767B1
(fr)
|
2005-03-24 |
2016-03-09 |
Millennium Pharmaceuticals, Inc. |
Anticorps se liant à l'OV064 et leurs procédés d'utilisation
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
EP1912658B1
(fr)
*
|
2005-07-27 |
2017-01-25 |
Alchemia Oncology Pty Limited |
Protocoles thérapeutiques utilisant le hyaluronan
|
NZ599176A
(en)
*
|
2005-08-03 |
2014-04-30 |
Immunogen Inc |
Immunoconjugate formulations
|
CA3000520C
(fr)
|
2005-08-24 |
2023-04-04 |
Immunogen, Inc. |
Procede de preparation de conjugues maytansinoides-anticorps
|
CN101287475B
(zh)
|
2005-09-07 |
2012-11-14 |
阿尔卡米亚肿瘤学股份有限公司 |
包含透明质酸和治疗抗体的治疗组合物以及制药用途
|
EA016186B1
(ru)
*
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
CN101365679B
(zh)
|
2005-10-26 |
2012-11-14 |
梅达莱克斯公司 |
制备cc-1065类似物的方法和化合物
|
WO2007059404A2
(fr)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Composes et conjugues cytotoxiques
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
EP1806365A1
(fr)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
|
RS52060B
(en)
|
2006-01-25 |
2012-04-30 |
Sanofi |
CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES
|
RU2489423C2
(ru)
*
|
2006-02-02 |
2013-08-10 |
Синтарга Б.В. |
Водорастворимые аналоги сс-1065 и их конъюгаты
|
EP1832577A1
(fr)
*
|
2006-03-07 |
2007-09-12 |
Sanofi-Aventis |
Promédicament amélioré d'analogues de CC-1065
|
EP1864682A1
(fr)
|
2006-06-09 |
2007-12-12 |
Sanofi-Aventis |
Dérivés de la Leptomycine
|
ME00581B
(fr)
|
2006-07-18 |
2011-12-20 |
Sanofi Aventis |
Anticorps antagoniste destiné au traitement du cancer
|
EP1914242A1
(fr)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
EP2121743B1
(fr)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
|
MX2009006277A
(es)
*
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
MX2009007987A
(es)
|
2007-01-25 |
2010-03-01 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
WO2008097497A2
(fr)
|
2007-02-02 |
2008-08-14 |
Adnexus, A Bristol-Myers Squibb R & D Company |
Blocage de voie de vegf
|
CL2008000510A1
(es)
*
|
2007-02-21 |
2008-08-22 |
Medarex Inc |
Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
EP2132312B1
(fr)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
|
JP2008297203A
(ja)
*
|
2007-05-29 |
2008-12-11 |
Chisso Corp |
複合体
|
DK2019104T3
(da)
*
|
2007-07-19 |
2013-12-16 |
Sanofi Sa |
Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
|
US9901567B2
(en)
|
2007-08-01 |
2018-02-27 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
SG10201407388XA
(en)
|
2007-08-29 |
2015-01-29 |
Sanofi Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
JP5951929B2
(ja)
|
2007-10-03 |
2016-07-13 |
コーネル ユニヴァーシティー |
Psma抗体を用いる増殖性障害の治療
|
EP2050764A1
(fr)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Nouveau format d'anticorps bispécifique polyvalent
|
DK2242772T3
(en)
*
|
2007-12-26 |
2015-01-05 |
Biotest Ag |
Immunoconjugates that targets CD138, and uses thereof
|
US9011864B2
(en)
*
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
US9446146B2
(en)
*
|
2007-12-26 |
2016-09-20 |
Biotest Ag |
Methods and agents for improving targeting of CD138 expressing tumor cells
|
KR101626416B1
(ko)
*
|
2007-12-26 |
2016-06-01 |
바이오테스트 아게 |
Cd138 표적 물질 및 이의 용도
|
AU2009208607B2
(en)
*
|
2008-01-31 |
2013-08-01 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
EP3692988A3
(fr)
|
2008-03-18 |
2020-10-14 |
Genentech, Inc. |
Combinaisons d'un conjugué de médicament-anticorps anti-her2 et 5-fu, anticorps anti-vegf, carboplatin ou abt869 et procédés d'utilisation
|
US8829159B2
(en)
|
2008-04-14 |
2014-09-09 |
The General Hospital Corporation |
Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
|
PT2281006T
(pt)
|
2008-04-30 |
2017-12-06 |
Immunogen Inc |
Agentes de reticulação e as suas utilizações
|
US20100092495A1
(en)
*
|
2008-04-30 |
2010-04-15 |
Immunogen Inc. |
Potent cell-binding agent drug conjugates
|
CN102099373A
(zh)
|
2008-05-22 |
2011-06-15 |
百时美施贵宝公司 |
基于纤连蛋白的多价支架结构域蛋白
|
WO2010027364A1
(fr)
|
2008-09-07 |
2010-03-11 |
Glyconex Inc. |
Anticorps anti-glycosphingolipide de type i étendu, dérivés de celui-ci et utilisation
|
EP3622968A1
(fr)
|
2008-10-31 |
2020-03-18 |
The General Hospital Corporation |
Compositions et procédés d'administration d'une substance à une cible biologique
|
WO2010062171A2
(fr)
|
2008-11-03 |
2010-06-03 |
Syntarga B.V. |
Nouveaux analogues de cc-1065 et leurs conjugués
|
JP5977522B2
(ja)
|
2009-02-05 |
2016-08-24 |
イミュノジェン・インコーポレーテッド |
新規ベンゾジアゼピン誘導体
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
WO2010096486A1
(fr)
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Procédés et kits pour le diagnostic d'un cancer et la prédiction d'une valeur thérapeutique
|
CA2759502C
(fr)
|
2009-04-29 |
2021-02-09 |
Bio-Rad Laboratories, Inc. |
Purification d'immunoconjugues
|
WO2010126552A1
(fr)
*
|
2009-04-30 |
2010-11-04 |
Immunogen, Inc. |
Conjugués de médicament d'agent de liaison cellulaire puissant
|
CA2939492C
(fr)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Immunoglobulines anti-cd52 humain
|
EP2430047B1
(fr)
|
2009-05-13 |
2018-03-28 |
i2 Pharmaceuticals, Inc. |
Molécules neutralisantes dirigées contre les virus de la grippe
|
KR102560218B1
(ko)
|
2009-06-03 |
2023-07-26 |
이뮤노젠 아이엔씨 |
접합 방법
|
WO2011028952A1
(fr)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
IN2012DN02780A
(fr)
|
2009-10-06 |
2015-09-18 |
Immunogen Inc |
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 항체 및 이의 용도
|
CA3014767C
(fr)
|
2010-02-24 |
2023-08-29 |
Immunogen, Inc. |
Anticorps du recepteur 1 du folate et immunoconjugues et leurs utilisations
|
AU2011226672B2
(en)
|
2010-03-12 |
2015-07-23 |
Immunogen, Inc. |
CD37-binding molecules and immunoconjugates thereof
|
CA2793753C
(fr)
|
2010-03-26 |
2018-06-05 |
Memorial Sloan-Kettering Cancer Center |
Anticorps anti-muc16 et leurs procedes d'utilisation
|
US9133239B2
(en)
|
2010-04-20 |
2015-09-15 |
The Research Foundation For The State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
|
ES2660428T3
(es)
|
2010-04-21 |
2018-03-22 |
Syntarga B.V. |
Conjugados de análogos de CC-1065 y conectores bifuncionales
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012019024A2
(fr)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Molécules se liant à her3 et leurs immunoconjugués
|
WO2012045085A1
(fr)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anticorps anti-ror1
|
CN103328505B
(zh)
|
2010-10-29 |
2015-12-02 |
伊缪诺金公司 |
非拮抗性egfr结合分子及其免疫偶联物
|
BR112013010544A2
(pt)
|
2010-10-29 |
2016-08-02 |
Immunogen Inc |
moléculas de ligação ao egfr e imunoconjugados das mesmas
|
WO2012075173A2
(fr)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions et procédé de désimmunisation de protéines
|
RS58033B1
(sr)
|
2010-12-09 |
2019-02-28 |
Immunogen Inc |
Postupci za pripremu naelektrisanih umreživača
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
RU2606016C2
(ru)
|
2011-01-14 |
2017-01-10 |
Редвуд Байосайнс, Инк. |
Меченые альдегидом полипептиды иммуноглобулина и способы их применения
|
WO2012106368A2
(fr)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Procédés d'inhibition du cancer de la prostate
|
ES2717657T3
(es)
|
2011-02-15 |
2019-06-24 |
Immunogen Inc |
Métodos para la preparación de conjugados
|
US20130344074A1
(en)
|
2011-03-16 |
2013-12-26 |
Sanofi |
Uses of a dual v region antibody-like protein
|
PL2691155T3
(pl)
|
2011-03-29 |
2019-06-28 |
Immunogen, Inc. |
Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem
|
SG193996A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
TWI597065B
(zh)
|
2011-06-10 |
2017-09-01 |
梅爾莎納醫療公司 |
蛋白質-聚合物-藥物共軛體
|
BR112013032928A2
(pt)
|
2011-06-21 |
2017-01-24 |
Immunogen Inc |
"derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
|
EP2736928B1
(fr)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Proteines "sur"-liantes dirigees contre erbb3
|
WO2013022855A1
(fr)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Anticorps avec points isoélectriques modifiés et immunofiltration
|
EP2758437B1
(fr)
|
2011-09-22 |
2020-06-03 |
Amgen Inc. |
Protéines de liaison à un antigène cd27l
|
CA2850624A1
(fr)
|
2011-10-03 |
2013-04-11 |
Moderna Therapeutics, Inc. |
Nucleosides, nucleotides et acides nucleiques modifies, et leurs utilisations
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CA3182462A1
(fr)
|
2011-10-10 |
2013-04-18 |
Xencor, Inc. |
Procede de purification d'anticorps
|
SG11201402343SA
(en)
|
2011-11-21 |
2014-06-27 |
Immunogen Inc |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
ES2684950T3
(es)
|
2011-12-08 |
2018-10-05 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a CD138
|
CN110201187A
(zh)
|
2011-12-16 |
2019-09-06 |
现代泰克斯公司 |
经修饰的核苷、核苷酸和核酸组合物
|
CA2859744A1
(fr)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Proteines substitutives de liaison
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
AU2013243952A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
WO2013151649A1
(fr)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Composés d'interaction avec des glycanes
|
US20130287797A1
(en)
|
2012-04-26 |
2013-10-31 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with bendamustine
|
US20130309224A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with rituximab
|
US8992915B2
(en)
|
2012-05-16 |
2015-03-31 |
Boehringer Ingelheim International Gmbh |
Combination of CD37 antibodies with ICE
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
MX2014014894A
(es)
|
2012-06-04 |
2015-02-20 |
Irm Llc |
Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
|
MX359599B
(es)
|
2012-10-04 |
2018-09-12 |
Immunogen Inc |
Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos.
|
US9902705B2
(en)
|
2012-10-24 |
2018-02-27 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
TWI664192B
(zh)
|
2012-11-20 |
2019-07-01 |
法商賽諾菲公司 |
抗ceacam5抗體及其用途
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
EP2928503B1
(fr)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugués de composés auristatine
|
WO2014093640A1
(fr)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Conjugués hydroxy-polymère-médicament-protéine
|
CA2896248A1
(fr)
|
2012-12-27 |
2014-07-03 |
Sanofi |
Anticorps anti-lamp1 et conjugues anticorps medicament, et utilisations associees
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014110601A1
(fr)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Nouvelles protéines hétérodimères
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP3434774A1
(fr)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Polynucléotides capteurs de signal servant à modifier les phénotypes cellulaires
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
SG10201706468RA
(en)
|
2013-02-08 |
2017-09-28 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2014124258A2
(fr)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
MA38396B1
(fr)
|
2013-03-15 |
2019-05-31 |
Novartis Ag |
Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2970486B1
(fr)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation de cellules t avec des anticorps bispecifiques et des fusions fc
|
EP3587448B1
(fr)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Protéines hétérodimériques
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
RS61778B1
(sr)
|
2013-05-06 |
2021-06-30 |
Scholar Rock Inc |
Kompozicije i postupci za modulaciju faktora rasta
|
JP6243521B2
(ja)
|
2013-05-30 |
2017-12-06 |
キニクサ ファーマシューティカルズ, リミテッド |
オンコスタチンm受容体抗原結合タンパク質
|
PT3019619T
(pt)
|
2013-07-11 |
2021-11-11 |
Modernatx Inc |
Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EP3055332B1
(fr)
|
2013-10-08 |
2019-09-25 |
ImmunoGen, Inc. |
Schémas posologiques d'immunoconjugués anti-folr1
|
MX2016004659A
(es)
|
2013-10-11 |
2017-08-02 |
Asana Biosciences Llc |
Conjugados proteina-polimero-farmaco.
|
JP6657075B2
(ja)
|
2013-10-11 |
2020-03-04 |
オックスフォード バイオセラピューティックス リミテッドOxford Biotherapeutics Ltd |
がん治療のためのly75に対する複合抗体
|
AU2014331714B2
(en)
|
2013-10-11 |
2019-05-02 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
KR20160099725A
(ko)
|
2014-01-10 |
2016-08-22 |
신톤 바이오파머슈티칼즈 비.브이. |
자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
|
MY177390A
(en)
|
2014-01-10 |
2020-09-14 |
Byondis Bv |
Method for purifying cys-linked antibody-drug conjugates
|
ES2575508T3
(es)
|
2014-01-10 |
2016-06-29 |
Synthon Biopharmaceuticals B.V. |
CAFs de duocarmicina que presentan una mejora en la actividad antitumoral in vivo
|
US9943606B2
(en)
|
2014-01-15 |
2018-04-17 |
Rutgers, The State University Of New Jersey |
Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3122757B1
(fr)
|
2014-02-28 |
2023-09-06 |
Hangzhou Dac Biotech Co., Ltd |
Lieurs chargés et leurs utilisations pour la conjugaison
|
BR112016020065A2
(pt)
|
2014-03-12 |
2018-02-20 |
Novartis Ag |
sítios específicos para modificar anticorpos para fazer imunoconjugados
|
ES2770684T3
(es)
|
2014-03-14 |
2020-07-02 |
Novartis Ag |
Moléculas de anticuerpos contra LAG-3 y usos de los mismos
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016014846A1
(fr)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2016020791A1
(fr)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Conjugués anticorps ckit-médicament
|
WO2016025480A1
(fr)
|
2014-08-11 |
2016-02-18 |
The General Hospital Corporation |
Cyclo-octènes pour réactions bio-orthogonales
|
BR112017001588A2
(pt)
|
2014-08-12 |
2017-11-21 |
Novartis Ag |
conjugados de anticorpo/fármaco anti-cdh6
|
CN113842468A
(zh)
|
2014-09-02 |
2021-12-28 |
伊缪诺金公司 |
用于配制抗体药物缀合物组合物的方法
|
MA54254A
(fr)
|
2014-09-03 |
2021-09-22 |
Immunogen Inc |
Dérivés de benzodiazépine cytotoxique
|
US9381256B2
(en)
|
2014-09-03 |
2016-07-05 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
WO2016054555A2
(fr)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Polythérapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
PE20171067A1
(es)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
US10525139B2
(en)
|
2014-11-05 |
2020-01-07 |
Dana-Farber Cancer Institute, Inc. |
Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016077526A1
(fr)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Composés interagissant avec le glycane et procédés d'utilisation
|
TN2017000173A1
(en)
|
2014-11-14 |
2018-10-19 |
Novartis Ag |
Antibody drug conjugates
|
MA40934A
(fr)
|
2014-11-19 |
2017-09-27 |
Immunogen Inc |
Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3および腫瘍抗原に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
US10335495B2
(en)
|
2014-12-04 |
2019-07-02 |
Celgene Corporation |
Biomolecule conjugates
|
EP3233918A1
(fr)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Polythérapies
|
WO2016105450A2
(fr)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Anticorps trispécifiques
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
SG11201707538XA
(en)
|
2015-03-17 |
2017-10-30 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
WO2016149485A1
(fr)
|
2015-03-17 |
2016-09-22 |
The Regents Of The University Of California |
Nouvelle chimio-immunothérapie pour cancer épithélial
|
KR20180002645A
(ko)
|
2015-04-07 |
2018-01-08 |
메모리얼 슬로안-케터링 캔서 센터 |
나노입자 면역컨쥬게이트
|
EP3310813A1
(fr)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Conjugués anticorps-médicament
|
JP2018524588A
(ja)
|
2015-06-26 |
2018-08-30 |
ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド |
骨髄由来サプレッサー細胞中のテトラスパニン33(Tspan33)を標的化するがん療法
|
WO2017004025A1
(fr)
|
2015-06-29 |
2017-01-05 |
Immunogen, Inc. |
Conjugués d'anticorps à cystéine modifiée
|
CA2991973C
(fr)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
EP3325485B1
(fr)
|
2015-07-21 |
2020-04-08 |
ImmunoGen, Inc. |
Procédés de préparation de dérivés de benzodiazépine cytotoxiques
|
EP3316902A1
(fr)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Polythérapies comprenant des molécules d'anticorps contre tim -3
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
EP3331569A1
(fr)
|
2015-08-07 |
2018-06-13 |
Gamamabs Pharma |
Anticorps, conjugués anticorps-médicaments et procédés d'utilisation
|
RU2749865C2
(ru)
|
2015-09-17 |
2021-06-17 |
Иммьюноджен, Инк. |
Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
|
AU2016324463B2
(en)
|
2015-09-17 |
2022-10-27 |
Modernatx, Inc. |
Polynucleotides containing a stabilizing tail region
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
CA3002097A1
(fr)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Composes interagissant avec le glycane et methodes d'utilisation
|
PT3380525T
(pt)
|
2015-11-25 |
2024-02-05 |
Immunogen Inc |
Formulações farmacêuticas e métodos que as utilizam
|
WO2017100372A1
(fr)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Anticorps hétérodimèes se liant à cd3 et psma
|
WO2017106656A1
(fr)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Molécules d'anticorps anti-pd-1 et leurs utilisations
|
AU2016369623A1
(en)
|
2015-12-17 |
2018-06-28 |
Novartis Ag |
Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
|
SG11201806478PA
(en)
|
2016-02-05 |
2018-08-30 |
Immunogen Inc |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
|
WO2017197045A1
(fr)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Synthèse totale convergente et énantiosélective d'analogues de la communesine
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
WO2018004338A1
(fr)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Tétrazine clivable utilisée dans l'activation de médicaments bio-orthogonaux
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR102649972B1
(ko)
|
2016-10-14 |
2024-03-22 |
젠코어 인코포레이티드 |
IL15/IL15Rα 이종이량체 Fc-융합 단백질
|
JP2020510608A
(ja)
|
2016-11-02 |
2020-04-09 |
デビオファーム インターナショナル, エス. アー. |
抗cd37イムノコンジュゲート療法を改善するための方法
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
WO2018094143A1
(fr)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Composés interagissant avec le glycane et méthodes d'utilisation
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3544983A2
(fr)
|
2016-11-23 |
2019-10-02 |
Immunogen, Inc. |
Sulfonation sélective de dérivés de benzodiazépine
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
CN116785450A
(zh)
|
2017-02-28 |
2023-09-22 |
伊缪诺金公司 |
具有自分解肽接头的类美登素衍生物和其缀合物
|
MX2019010202A
(es)
|
2017-03-03 |
2019-10-02 |
Seattle Genetics Inc |
Compuestos que interactuan con glicano y metodos de uso.
|
EP3592393B1
(fr)
|
2017-03-10 |
2021-12-01 |
QuiaPEG Pharmaceuticals AB |
Conjugués libérables
|
WO2018185618A1
(fr)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
|
TW201839001A
(zh)
|
2017-04-20 |
2018-11-01 |
美商伊繆諾金公司 |
細胞毒性苯并二氮平衍生物及其綴合物
|
JP7303182B2
(ja)
|
2017-04-21 |
2023-07-04 |
メリタス エルエルシー |
糖尿病関連用途のための方法及び抗体
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018209239A1
(fr)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2018237262A1
(fr)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Procédés de production de matrices polymères transportant des médicaments, et conjugués protéine-polymère-médicament
|
WO2018237173A1
(fr)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
|
WO2019006007A1
(fr)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Régimes posologiques pour anticorps anti-tim3 et leurs utilisations
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
CA3070095A1
(fr)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
Regimes posologiques pour des anticorps anti-lag3 et leurs utilisations
|
WO2019016772A2
(fr)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
Compositions et procédés permettant de traiter un cancer
|
EP3672615A4
(fr)
|
2017-08-22 |
2021-04-21 |
Purdue Research Foundation |
Conjugués thérapeutiques et de radio-imagerie à base de fbsa ciblant des cancers positifs pour l'anhydrase carbonique
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
WO2019125732A1
(fr)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Protéines de fusion il-2 fc modifiées
|
WO2019129137A1
(fr)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
Anticorps anti-lag-3 et utilisations associées
|
WO2019133652A1
(fr)
|
2017-12-28 |
2019-07-04 |
Immunogen, Inc. |
Dérivés de benzodiazépine
|
CA3096052A1
(fr)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Anticorps heterodimeres qui se lient a la proteine d'activation des fibroblastes
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CA3097741A1
(fr)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
US20210299286A1
(en)
|
2018-05-04 |
2021-09-30 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
CA3101790A1
(fr)
|
2018-05-30 |
2019-12-05 |
Debiopharm International, S.A. |
Regimes posologiques d'immunoconjugue anti-cd37
|
WO2019232244A2
(fr)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Molécules d'anticorps anti-cd73 et leurs utilisations
|
CN112654394A
(zh)
|
2018-06-19 |
2021-04-13 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
KR20210028204A
(ko)
|
2018-07-02 |
2021-03-11 |
암젠 인크 |
항-steap1 항원 결합 단백질
|
WO2020021465A1
(fr)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Procédé de traitement de tumeurs neuroendocrines
|
US11357828B2
(en)
|
2018-09-12 |
2022-06-14 |
Quiapeg Pharmaceuticals Ab |
Releasable GLP-1 conjugates
|
AU2019355971A1
(en)
|
2018-10-03 |
2021-05-06 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
EP3873534A1
(fr)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Conjugués anticorps-médicament modifiés par une cystéine avec des lieurs contenant des peptides
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
JP2022514017A
(ja)
|
2018-12-20 |
2022-02-09 |
ノバルティス アーゲー |
医薬の組み合わせ
|
CA3234463A1
(fr)
|
2018-12-21 |
2019-12-18 |
Novartis Ag |
Anticorps diriges contre pmel17 et conjugues de ces derniers
|
KR20210124260A
(ko)
|
2019-02-07 |
2021-10-14 |
사노피 |
폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
|
EP3693023A1
(fr)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
CA3132185A1
(fr)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Anticorps heterodimeres qui se lient a enpp3 et cd3
|
SG11202109986TA
(en)
|
2019-03-20 |
2021-10-28 |
Univ California |
Claudin-6 antibodies and drug conjugates
|
CN113661172A
(zh)
|
2019-03-29 |
2021-11-16 |
伊缪诺金公司 |
用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
|
MA55519A
(fr)
|
2019-03-29 |
2022-02-09 |
Atarga Llc |
Anticorps anti-fgf23
|
HRP20231619T1
(hr)
|
2019-04-26 |
2024-04-26 |
Immunogen, Inc. |
Derivati kamptotecina
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
WO2020256546A1
(fr)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Composés pour libération de chimie click rapide et efficace
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
EP4087614A1
(fr)
|
2020-01-09 |
2022-11-16 |
Mersana Therapeutics, Inc. |
Conjugués anticorps-médicament spécifiques à un site avec des lieurs contenant des peptides
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
CN115551552A
(zh)
|
2020-02-25 |
2022-12-30 |
祐方有限公司 |
喜树碱衍生物及其缀合物
|
IL297221A
(en)
|
2020-04-24 |
2022-12-01 |
Sanofi Sa |
Antitumor combinations containing conjugates of antibodies to ceacam5 and folfiri
|
MX2022013404A
(es)
|
2020-04-24 |
2022-11-14 |
Sanofi Sa |
Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
|
CN115427083A
(zh)
|
2020-04-24 |
2022-12-02 |
赛诺菲 |
含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
|
AU2021260823A1
(en)
|
2020-04-24 |
2023-01-05 |
Sanofi |
Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFOX
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
EP3909601A1
(fr)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
Nouvel anticorps se liant spécifiquement au ceacam 1/3/5 humain et son utilisation
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2022010797A2
(fr)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Nouveaux maytansinoïdes en tant que charges utiles d'adc et leur utilisation pour le traitement du cancer
|
CN111777536B
(zh)
*
|
2020-07-14 |
2022-03-01 |
常州大学 |
一种制备不对称二硫醚的方法
|
WO2022026592A2
(fr)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Molécules d'anticorps contre le coronavirus et leurs utilisations
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
MX2023006010A
(es)
|
2020-11-24 |
2023-06-08 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
CA3212665A1
(fr)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Anticorps heterodimeriques se liant a cd3 et a cldn6
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
WO2022195551A1
(fr)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarqueurs pour le cancer et leurs méthodes d'utilisation
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
CA3216880A1
(fr)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Conjugues anticorps-medicament et leurs procedes de fabrication
|
WO2023031445A2
(fr)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Nouveaux variants d'aminoacyl-arnt synthétase pour l'expansion de code génétique dans des eucaryotes
|
CA3237142A1
(fr)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Combinaisons antitumorales contenant des conjugues anticorps-medicament anti-ceacam5 et des anticorps anti-vegfr-2
|
WO2023094525A1
(fr)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Conjugués anticorps-charge utile améliorés (apc) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
|
EP4186529A1
(fr)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Conjugués anticorps-charge utile améliorés (apcs) préparés par conjugaison spécifique à un site à l'aide d'une expansion de code génétique
|
TW202339804A
(zh)
|
2021-12-02 |
2023-10-16 |
法商賽諾菲公司 |
在癌症療法中用於患者選擇的cea測定
|
WO2023099682A1
(fr)
|
2021-12-02 |
2023-06-08 |
Sanofi |
Polythérapie à base de ceacam5 adc anti-pd-1/pd-l1
|
WO2023104941A1
(fr)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Charges utiles hydrophiles fonctionnalisées à la tétrazine destinées à la préparation de conjugués de ciblage
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023158305A1
(fr)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B.V. |
Protéine il12 masquée
|
WO2024013723A1
(fr)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations
|
WO2024023735A1
(fr)
|
2022-07-27 |
2024-02-01 |
Mediboston Limited |
Dérivés d'auristatine et conjugués de ceux-ci
|
WO2024030976A2
(fr)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique
|
WO2024080872A1
(fr)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Bicyclononènes contraints
|